Inhaled therapeutics for prevention and treatment of pneumonia

Bibliography

• The World Health Report 2004 – Changing History. Geneva: World Health Organization, 2004
   Google Scholar
• File TM. Community-acquired pneumonia. Lancet 2003;362(9400):1991-2001
   PubMed Web of Science ®Google Scholar
• Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc Am Thorac Soc 2005;2(5):445-8
   PubMedGoogle Scholar
• Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109(5):571-7
   PubMed Web of Science ®Google Scholar
• Martin TR, Frevert CW. Innate immunity in the lungs. Proc Am Thorac Soc 2005;2(5):403-11
   PubMedGoogle Scholar
• Rogan MP, Geraghty P, Greene CM, et al. Antimicrobial proteins and polypeptides in pulmonary innate defence. Respir Res 2006;7:29
   PubMed Web of Science ®Google Scholar
• Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 2001;13(1):89-95
   PubMed Web of Science ®Google Scholar
• Flanders SACH, Saint S. Nosocomial pneumonia: state of the science. Am J Infect Control 2006;(34):84-93
   PubMedGoogle Scholar
• Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109(5):571-7
   Google Scholar
• Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006;354(3):291-3
   PubMed Web of Science ®Google Scholar
• Tarran R, Donaldson S, Boucher RC. Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Respir Crit Care Med 2007;28(3):295-302
   PubMed Web of Science ®Google Scholar
• Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21(2):77-83
   PubMed Web of Science ®Google Scholar
• Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153(5):1503-9
   PubMed Web of Science ®Google Scholar
• Sood N, Bennett WD, Zeman K, et al. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med 2003;167(2):158-63
   PubMed Web of Science ®Google Scholar
• Wark PA, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2003(1):CD001506
   Google Scholar
• Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354(3):241-50
   PubMed Web of Science ®Google Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-40
   PubMed Web of Science ®Google Scholar
• Kerem E, Bistritzer T, Hanukoglu A, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999;341(3):156-62
   PubMedGoogle Scholar
• Williams OW, Sharafkhaneh A, Kim V, et al. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006;34(5):527-36
   Google Scholar
• Evans CM, Kim K, Tuvim MJ, et al. Mucus hypersecretion in asthma: causes and effects. Curr Opin Pulm Med 2009;15(1):4-11
   PubMed Web of Science ®Google Scholar
• Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007;58:157-70
   PubMed Web of Science ®Google Scholar
• Evans CM, Williams OW, Tuvim MJ, et al. Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. Am J Respir Cell Mol Biol 2004;31(4):382-94
   PubMed Web of Science ®Google Scholar
• Williams OW, Sharafkhaneh A, Kim V, et al. Airway mucus: from production to secretion. Am J Respir Cell Mol Biol 2006;34(5):527-36
   PubMed Web of Science ®Google Scholar
• Akinbi HT, Epaud R, Bhatt H, et al. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol 2000;165(10):5760-6
   PubMed Web of Science ®Google Scholar
• Bals R, Weiner DJ, Moscioni AD, et al. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999;67(11):6084-9
   PubMed Web of Science ®Google Scholar
• Cole AM, Liao HI, Stuchlik O, et al. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002;169(12):6985-91
   PubMed Web of Science ®Google Scholar
• Cole AM, Thapa DR, Gabayan V, et al. Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J Leukoc Biol 2005;78(5):1081-5
   PubMed Web of Science ®Google Scholar
• Moser C, Weiner DJ, Lysenko E, et al. beta-Defensin 1 contributes to pulmonary innate immunity in mice. Infect Immun 2002;70(6):3068-72
   PubMed Web of Science ®Google Scholar
• Evans SE, Hahn PY, McCann F, et al. Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol 2005;32(6):490-7
   PubMed Web of Science ®Google Scholar
• Agusti C, Rano A, Rovira M, et al. Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients. Thorax 2004;59(12):1081-8
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300(5625):1524-5
   PubMed Web of Science ®Google Scholar
• Boldrick JC, Alizadeh AA, Diehn M, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA 2002;99(2):972-7
   PubMed Web of Science ®Google Scholar
• Kapetanovic R, Cavaillon JM. Early events in innate immunity in the recognition of microbial pathogens. Expert Opin Biol Ther 2007;7(6):907-18
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. TLR signaling. Cell Death Differ 2006;13(5):816-25
   PubMed Web of Science ®Google Scholar
• Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003;15(4):396-401
   PubMed Web of Science ®Google Scholar
• Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107(1):13-9
   PubMed Web of Science ®Google Scholar
• Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 2004;4(7):512-20
   PubMed Web of Science ®Google Scholar
• Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007;44(12):1549-54
   PubMed Web of Science ®Google Scholar
• Kanistanon D, Hajjar AM, Pelletier MR, et al. A Francisella mutant in lipid A carbohydrate modification elicits protective immunity. PLoS Pathog 2008;4(2):e24
   PubMed Web of Science ®Google Scholar
• Lembo A, Pelletier M, Iyer R, et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol 2008;180(11):7574-81
   PubMed Web of Science ®Google Scholar
• Luhrmann A, Deiters U, Skokowa J, et al. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of Mycoplasma fermentans after pulmonary application. Infect Immun 2002;70(7):3785-92
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46(5):1341-9
   PubMed Web of Science ®Google Scholar
• Raberg L, Sim D, Read AF. Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science 2007;318(5851):812-4
   PubMed Web of Science ®Google Scholar
• Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha + -thalassemia and the sickle cell trait. Nat Genet 2005;37(11):1253-7
   PubMed Web of Science ®Google Scholar
• Evans SE, Scott BL, Clement CG, et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2009 Mar 27 [Epub ahead of print] PMID: 19329554
   PubMedGoogle Scholar
• Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285(21):2763-73
   PubMed Web of Science ®Google Scholar
• Hilleman MR. Overview: cause and prevention in biowarfare and bioterrorism. Vaccine 2002;20(25-26):3055-67
   PubMed Web of Science ®Google Scholar
• Wayne Conlan J, Shen H, Kuolee R, et al. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine 2005;23(19):2477-85
   PubMed Web of Science ®Google Scholar
• Wilkening DA. Sverdlovsk revisited: modeling human inhalation anthrax. Proc Natl Acad Sci USA 2006;103(20):7589-94
   PubMed Web of Science ®Google Scholar
• Tuvim MJ, Evans SE, Clement CG, et al. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 2009;4(1):e4176
   PubMed Web of Science ®Google Scholar
• Clement CG, Evans SE, Evans CM, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med 2008;177(12):1322-30
   PubMed Web of Science ®Google Scholar
• Moghaddam SJ, Clement CG, De la Garza MM, et al. Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol 2008;38(6):629-38
   PubMed Web of Science ®Google Scholar
• Brandl K, Plitas G, Mihu CN, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008;455(7214):804-7
   PubMed Web of Science ®Google Scholar
• Hoogerwerf JJ, de Vos AF, Bresser P, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008;178(1):34-41
   PubMed Web of Science ®Google Scholar
• Reppe K, Tschernig T, Luhrmann A, et al. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am J Respir Cell Mol Biol 2009;40(4):474-81
   PubMedGoogle Scholar
• Bagchi A, Herrup EA, Warren HS, et al. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol 2007;178(2):1164-71
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7(3):179-90
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449(7164):819-26
   PubMed Web of Science ®Google Scholar
• Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007;447(7147):972-8
   PubMed Web of Science ®Google Scholar
• Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005;171(10):1142-9
   PubMed Web of Science ®Google Scholar
• Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5(9):2316-23
   PubMed Web of Science ®Google Scholar
• Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349(26):2527-39
   PubMed Web of Science ®Google Scholar
• Kinnula V, Mattson K, Cantell K. Pharmacokinetics and toxicity of inhaled human interferon-alpha in patients with lung cancer. J Interferon Res 1989;9(4):419-23
   PubMedGoogle Scholar
• Maasilta P, Halme M, Mattson K, et al. Pharmacokinetics of inhaled recombinant and natural alpha interferon. Lancet 1991;337(8737):371
   PubMed Web of Science ®Google Scholar
• Kinnula V, Cantell K, Mattson K. Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma. Eur J Cancer 1990;26(6):740-1
   PubMed Web of Science ®Google Scholar
• Maasilta P, Holsti LR, Halme M, et al. Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992;23(4):863-8
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1998;158(4):1156-62
   PubMed Web of Science ®Google Scholar
• Giosue S, Casarini M, Ameglio F, et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur Cytokine Netw 2000;11(1):99-104
   PubMed Web of Science ®Google Scholar
• Martin RJ, Boguniewicz M, Henson JE, et al. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148(6 Pt 1):1677-82
   PubMedGoogle Scholar
• Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995;95(1 Pt 1):133-5
   PubMed Web of Science ®Google Scholar
• Condos R, Raju B, Canova A, et al. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun 2003;71(4):2058-64
   PubMed Web of Science ®Google Scholar
• Raju B, Hoshino Y, Kuwabara K, et al. Aerosolized gamma interferon (IFN-gamma) induces expression of the genes encoding the IFN-gamma-inducible 10-kilodalton protein but not inducible nitric oxide synthase in the lung during tuberculosis. Infect Immun 2004;72(3):1275-83
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349(9064):1513-5
   PubMed Web of Science ®Google Scholar
• Condos R, Hull FP, Schluger NW, et al. Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis. Chest 2004;125(6):2146-55
   PubMed Web of Science ®Google Scholar
• Moss RB, Mayer-Hamblett N, Wagener J, et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005;39(3):209-18
   PubMed Web of Science ®Google Scholar
• Nakos G, Malamou-Mitsi VD, Lachana A, et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med 2002;30(7):1488-94
   PubMed Web of Science ®Google Scholar
• Virgolini I, Kurtaran A, Leimer M, et al. Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med 1997;38(9):1475-81
   PubMed Web of Science ®Google Scholar
• Rao RD, Anderson PM, Arndt CA, et al. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 2003;26(5):493-8
   PubMed Web of Science ®Google Scholar
• Niven RW, Whitcomb KL, Shaner L, et al. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 1995;12(9):1343-9
   PubMed Web of Science ®Google Scholar
• Machida M, Hayashi M, Awazu S. Pulmonary absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after intratracheal administration to rats. Biol Pharm Bull 1996;19(2):259-62
   PubMed Web of Science ®Google Scholar
• Gatmaitan BG, Carruthers MM, Lerner AM. Gentamicin in treatment of primary Gram-negative pneumonias. Am J Med Sci 1970;260(2):90-4
   PubMed Web of Science ®Google Scholar
• Pines A, Raafat H, Plucinski K. Gentamicin and colistin in chronic purulent bronchial infections. Br Med J 1967;2(5551):543-5
   PubMed Web of Science ®Google Scholar
• Klastersky J, Geuning C, Mouawad E, et al. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972;61(2):117-20
   PubMed Web of Science ®Google Scholar
• Pines A, Raafat H, Siddiqui GM, et al. Treatment of severe pseudomonas infections of the bronchi. Br Med J 1970;1(5697):663-5
   PubMed Web of Science ®Google Scholar
• Odio W, Van Laer E, Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 1975;15(7):518-24
   PubMed Web of Science ®Google Scholar
• Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005;128(2):545-52
   PubMed Web of Science ®Google Scholar
• Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999;65(3):245-50
   PubMed Web of Science ®Google Scholar
• Valcke YJ, Vogelaers DP, Colardyn FA, et al. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992;101(4):1028-32
   PubMed Web of Science ®Google Scholar
• Braude AC, Hornstein A, Klein M, et al. Pulmonary disposition of tobramycin. Am Rev Respir Dis 1983;127(5):563-5
   PubMedGoogle Scholar
• Kuhn RJ. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 2002;22(3 Pt 2):80S-5S
   PubMed Web of Science ®Google Scholar
• Goldstein I, Wallet F, Nicolas-Robin A, et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002;166(10):1375-81
   PubMed Web of Science ®Google Scholar
• Goldstein I, Wallet F, Robert J, et al. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002;165(2):171-5
   PubMed Web of Science ®Google Scholar
• Klastersky J, Carpentier-Meunier F, Kahan-Coppens L, et al. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest 1979;75(5):586-91
   PubMed Web of Science ®Google Scholar
• Flume P, Klepser ME. The rationale for aerosolized antibiotics. Pharmacotherapy 2002;22(3 Pt 2):71S-9S
   PubMed Web of Science ®Google Scholar
• Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155(1):93-9
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149(3):443-8
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis Suppl 1990;74:218-34
   PubMedGoogle Scholar
• Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986;5(4):319-24
   PubMedGoogle Scholar
• Collins T, Gerding DN. Aminoglycosides versus beta-lactams in gram-negative pneumonia. Semin Respir Infect 1991;6(3):136-46
   PubMedGoogle Scholar
• Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179(5):1190-6
   PubMed Web of Science ®Google Scholar
• Valcke Y, Pauwels R, Van der Straeten M. The penetration of aminoglycosides into the alveolar lining fluid of rats. The effect of airway inflammation. Am Rev Respir Dis 1990;142(5):1099-103
   PubMedGoogle Scholar
• Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4):859-68
   PubMed Web of Science ®Google Scholar
• Davis KK, Kao PN, Jacobs SS, et al. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2
   PubMedGoogle Scholar
• McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther Drug Monit 1989;11(6):692-5
   PubMed Web of Science ®Google Scholar
• Dopfer R, Brand P, Mullinger B, et al. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods. J Physiol Pharmacol 2007;58(Suppl 5)(Pt 1):141-54
   PubMedGoogle Scholar
• Lenoir G, Antypkin YG, Miano A, et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007;9(Suppl 1):11-20
   PubMedGoogle Scholar
• Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740-6
   PubMed Web of Science ®Google Scholar
• Ratjen F, Doring G. Cystic fibrosis. Lancet 2003;361(9358):681-9
   PubMed Web of Science ®Google Scholar
• Canton R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005;11(9):690-703
   PubMed Web of Science ®Google Scholar
• Sexauer WP, Fiel SB. Aerosolized antibiotics in cystic fibrosis. Semin Respir Crit Care Med 2003;24(6):717-26
   PubMed Web of Science ®Google Scholar
• Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Aust Paediatr J 1984;20(1):43-5
   PubMedGoogle Scholar
• Wall MA, Terry AB, Eisenberg J, et al. Inhaled antibiotics in cystic fibrosis. Lancet 1983;1(8337):1325
   PubMed Web of Science ®Google Scholar
• Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6(2):91-8
   PubMed Web of Science ®Google Scholar
• Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7(4):265-71
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
   PubMed Web of Science ®Google Scholar
• Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121(1):55-63
   PubMed Web of Science ®Google Scholar
• Stephens D, Garey N, Isles A, et al. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983;2(3):209-11
   PubMedGoogle Scholar
• Schaad UB, Wedgwood-Krucko J, Suter S, et al. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111(4):599-605
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Barker AF. Bronchiectasis. N Engl J Med 2002;346(18):1383-93
   PubMed Web of Science ®Google Scholar
• Rubin BK. Aerosolized antibiotics for non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2008;21(1):71-6
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005;127(4):1420-6
   PubMed Web of Science ®Google Scholar
• Dodek P, Keenan S, Cook D, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med 2004;141(4):305-13
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos II, Bliziotis IA, et al. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006;10(4):R123
   PubMed Web of Science ®Google Scholar
• Rathgeber J, Zielmann S, Panzer C, et al. Prevention of pneumonia by endotracheal micronebulization of tobramycin. Anasthesiol Intensivmed Notfallmed Schmerzther 1993;28(1):23-9
   PubMedGoogle Scholar
• Klastersky J, Huysmans E, Weerts D, et al. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 1974;65(6):650-4
   PubMed Web of Science ®Google Scholar
• Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36
   PubMedGoogle Scholar
• Falagas ME, Agrafiotis M, Athanassa Z, et al. Administration of antibiotics via the respiratory tract as monotherapy for pneumonia. Expert Rev Anti Infect Ther 2008;6(4):447-52
   PubMed Web of Science ®Google Scholar
• Ghannam DE, Rodriguez GH, Raad II, et al. Inhaled aminoglycosides in cancer patients with ventilator-associated gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009;28(3):253-9
   PubMedGoogle Scholar
• Palmer LB, Smaldone GC, Chen JJ, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008;36(7):2008-13
   PubMed Web of Science ®Google Scholar
• Morosini MI, Garcia-Castillo M, Loza E, et al. Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips. J Clin Microbiol 2005;43(9):4480-5
   PubMed Web of Science ®Google Scholar
• Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43(Suppl 2):S89-S4
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant gram-negative bacteria: a prospective study. Respir Med 2008;102(3):407-12
   PubMed Web of Science ®Google Scholar
• Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41(5):754-7
   PubMed Web of Science ®Google Scholar
• Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm 2005;62(1):39-47
   PubMed Web of Science ®Google Scholar
• Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162(1):328-30
   PubMed Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(9):921-8
   PubMed Web of Science ®Google Scholar
• Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006;38(5):327-37
   PubMed Web of Science ®Google Scholar
• Safdar A. Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. Oncologist 2007;12(Suppl 2):2-6
   PubMed Web of Science ®Google Scholar
• Safdar ARG, Lichtiger B, Dickey BF, et al. Recombinant interferon gamma 1 b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006;106(12):2664-71
   PubMed Web of Science ®Google Scholar
• Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003;37(Suppl 3):S281-92
   Google Scholar
• Garcia-Vidal CUA, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47(8):1041-50
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;100(3):581-9
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 2006;44(5):445-9
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Bernard EM, Hauser M, et al. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988;32(11):1676-9
   PubMed Web of Science ®Google Scholar
• Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41(2):259-61
   PubMed Web of Science ®Google Scholar
• Koizumi T, Kubo K, Kaneki T, et al. Pharmacokinetic evaluation of amphotericin B in lung tissue: lung lymph distribution after intravenous injection and airspace distribution after aerosolization and inhalation of amphotericin B. Antimicrob Agents Chemother 1998;42(7):1597-600
   PubMed Web of Science ®Google Scholar
• Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006;6(11):2765-73
   PubMed Web of Science ®Google Scholar
• Drew RH, Dodds Ashley E, Benjamin DK Jr, et al. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77(2):232-7
   PubMed Web of Science ®Google Scholar
• Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at stanford university medical center. Clin Infect Dis 2001;33(5):629-40
   PubMed Web of Science ®Google Scholar
• Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72(3):545-8
   PubMed Web of Science ®Google Scholar
• Boots RJ, Paterson DL, Allworth AM, et al. Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF. Thorax 1999;54(11):1047-9
   PubMed Web of Science ®Google Scholar
• Safdar A, O'Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 2004;34(5):467-8
   PubMed Web of Science ®Google Scholar
• Dhand R, Guntur VP. How best to deliver aerosol medications to mechanically ventilated patients. Clin Chest Med 2008;29(2):277-96, vi
   PubMed Web of Science ®Google Scholar
• MacIntyre NR, Silver RM, Miller CV, et al. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985;13(2):81-4
   PubMed Web of Science ®Google Scholar
• Aerosol consensus statement-1991. American Association for Respiratory Care. Respir Care 1991;36(9):916-21
   PubMedGoogle Scholar
• Dhand R, Sohal H. Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008;5(1):9-18
   PubMed Web of Science ®Google Scholar
• Blanchard JDCD, et al. Lung deposition of interferon gamma – 1b following inhalation via AERx System vs. Respirgard II™ nebulizer. Am J Respir Crit Care Med 2003;167:A373 [Meeting Abstract]
   Google Scholar
• Watts AB, McConville JT, Williams RO. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 2008;34(9):913-22
   PubMed Web of Science ®Google Scholar